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Abstract 
Purpose: Epilepsy is a disease of neurological character. Approximately one third of epileptic patients demonstrate 
a drug-resistant phenotype, which is associated with the development of drug-resistant epilepsy. The multidrug 
resistance protein 1 and glycoprotein P, encoded by MDR1, play a significant role in the transmembrane transport 
of anti-epileptic agents. Single nucleotide polymorphism C3435T (rs1045642) within MDR1 gene may be associated 
with an increased expression of P-gp which affects the levels of antiepileptic drugs in plasma. The presented studies 
analysed the association between C3435T polymorphism of MDR1 gene and the incidence of drug-resistant epilepsy 
in the population of Polish children.
Methods: C3435T polymorphism of MDR1 gene was analysed by the high resolution melting technique in a group 
of patients with drug-resistant (n = 106) and drug-responsive epilepsy (n = 67), as well as in non-epileptic children 
(n = 98) hospitalised at the Department of Neurology, Polish Mother’s Memorial Hospital in Lodz. Genotype and allele 
distributions were evaluated and their compatibility with the Hardy–Weinberg distribution was assessed by means 
of the χ2 test. Genotype and allele evaluation, regarding their relationship with a given feature, was supported by an 
analysis of odds ratio and 95 % confidence interval, calculated according to the logistic regression model.
Results: An association was observed between the incidence rate of DRE and the presence of C allele in C3435T 
polymorphism of MDR1 gene, which may enhance the risk of the disease. The T allele may then play a protective 
role. No differences were found in the studied groups, regarding either genotype or allele distribution in reference to 
patient’s gender or concomitant diseases.
Conclusion: Following the obtained results, C3435T polymorphism of MDR1 gene may be connected with the  
incidence of drug-resistant epilepsy in the population of Polish children.
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Background
Epilepsy is one of the most frequent diseases of the nerv-
ous system, with prevalence rate estimated at approx. 1 % 
of the population in the world. The incidence of epilepsy 
is slightly higher in men than in women, while present-
ing significantly higher rates in children and in subjects 
above 65 years. The average incidence rate in the world 
population amounts to 50–70/100,000/year. In Poland, 
the number of affected subjects approaches 400,000 with 
the incidence of 7/1000 inhabitants [1]. For comparison, 
in the Asian populations, e.g., in Japan, the incidence is 
1.5/1000 and in India, 5.59/1000 [1, 2].
The basic treatment of epilepsy consists of a wide range 
of pharmacological substances—anticonvulsant medica-
tions. However, despite the constant development of new 
anticonvulsants with various molecular mechanisms of 
action, the fully effective pharmacological treatment of 
epilepsy has not yet been reached. In some of the patients, 
so-called, DRE may occur, as a serious clinical problem.
There are two main theories to explain the phenomenon 
of drug-resistance. The hypothesis of transporters assumes 
that the expression or function of multidrug transporters 
gets enhanced in the brain, thus suppressing the access of 
antiepileptic drugs to the central nervous system. The other 
hypothesis is based on the assumption that epilepsy-related 
changes induce lower sensitivity to anticonvulsant [3].
Despite the increasing knowledge of suspected risk 
factors of DRE, it still unclear why the responsiveness 
to pharmacological treatment may vary significantly 
between epilepsy patients with supposedly similar clini-
cal manifestations of the disease. The suggested deter-
minants of DRE include genetic factors and varying 
pharmacodynamic and pharmacokinetic features of 
administered drugs [4–7].
The to-date’s literature data indicate a significant role 
of MDR 1 and P-gp, encoded by MDR1, in the trans-
membrane transport of anti-epileptic agents [8–10]. The 
C3435T polymorphism (rs1045642) of MDR1 gene has 
been suggested as one of the genetic factors underlying 
DRE phenomenon [8–13]. It has been demonstrated that 
C3435T polymorphism determines the modified expres-
sion of MDR1 gene and thus the activity of P-gp, which 
plays a significant role in the transmembrane drug trans-
port [10]. It has been demonstrated that P-gp participates 
in the transport of phenobarbital, carbamazepine, pheny-
toin, lamotrigine, felbamate and gabapentin through the 
blood–brain barrier, as well as through the cellular mem-
branes of astrocytes and neurons in an epileptic focus. 
The results of the studies indicate participation of P-gp in 
the pathogenesis of DRE [10].
The MDR1 gene polymorphism, while structuring the 
variable expression of P-gp, may then control the efficacy 
of anti-epileptic therapy. An increased expression of this 
gene leads to higher volumes of P-gp in the endothelial 
cells of the blood–brain barrier and in astrocytes. This 
process results in decreasing the parenchymal concentra-
tions of drugs, despite achieved therapeutic level in blood 
[10, 13]. Importantly, in patients with DRE, evaluated by 
van Vliet et al. and Lazarowski et al., the homozygotic CC 
genotype was associated with increased P-gp expression, 
which affected the concentration levels of anti-epileptic 
drugs in plasma [10, 13].
However, the currently available literature data lack 
an unequivocal response to the question about the exact 
role of the MDR1 gene C3435T polymorphism in the 
development of DRE in children [12–17].
The goal of the study was to analyse the association 
between C3435T polymorphism of MDR1 gene and DRE 
in the population of Polish children.
Methods
Patients
Whole blood samples (1 ml), used as material for molec-
ular studies, were collected from children with DRE 
(n = 106) and drug-responsive (n = 67) epilepsy, as well 
as from non-epileptic children (n  =  98), hospitalised at 
the Department of Neurology, Polish Mother’s Memorial 
Hospital, Research Institute, in the years 2010–2016. The 
group of children with DRE included 52 boys and 54 girls 
and the group of therapy responders included 35 boys and 
32 girls, while the group of non-epileptic children com-
prised 52 boys and 46 girls. The demographic parameters 
of the study groups were not significantly different (see 
Table 1). All of the studied individuals, patients and con-
trols were Caucasians from the same ethnic and geograph-
ical origins, living in the Lodz region of central Poland.
All the epilepsy patients were subjected to pharmaco-
therapy. The administered medicinal agents included: 
CBZ, topiramat, OXC, GBP, LTG and LEV—all in various 
doses and configurations, depending on patient’s health 
status. A formal consent was obtained from the Bioethi-
cal Committee of the Institute of the Polish Mother’s 
Table 1 The number and age of the patients submitted to MDR1 gene polymorphism studies
Children with drug-resistant  
epilepsy (n = 106)
Children with drug-responsive  
epilepsy (n = 67)
Healthy children (n = 98)
Age (range) 1–15 years Age (range) 1–16 years Age (range) 4–14 years
Age (mean) 8.5 ± 4.84 Age (mean) 8.2 ± 4.019 Age (mean) 8.3 ± 4.64
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Memorial Hospital in Lodz (decision of 15th Decem-
ber 2010). Genetic studies of MDR1 gene C3435T poly-
morphism were performed at the Laboratory of Cancer 
Genetics, Department of Clinical Pathomorphology, Insti-
tute of the Polish Mother’s Memorial Hospital in Lodz.
HRM analyses
Genomic DNA was prepared, using DNeasy Blood & Tis-
sue Kit (Qiagen GmbH, Hilden, Germany) according to 
the manufacturer instruction. PCR products for the ana-
lysed variants were analysed by HRM analysis. Real-time 
PCR cycling and conditions and primers for HRM analy-
sis of all the examined MDR1 SNPs are summarized in 
Table 2. The analysis of the SNPs was performed with sup-
port of a Light Cycler® 480 High Resolution Melting Mas-
ter Kit (Roche, Mannheim, Germany), according to the 
manufacturer’s recommendations. A non-template con-
trol contained water, instead of genomic DNA, as a nega-
tive control. Additionally, positive controls (DNA samples 
with known genotype) were employed in each run of HRM 
analysis. PCR amplification was performed in a LightCy-
cler® 96 (Roche, Mannheim, Germany) Thermocycler. The 
collected data were analysed, using the LightCycler® 96 
software version SW 1.1 (Roche, Mannheim, Germany).
Statistical analysis
Genotype and allele distributions were evaluated and 
their compatibility with HWE distribution was assessed 
by means of the χ2 test. Differences between distribu-
tions in particular groups were evaluated also by the χ2 
test. All multivariate models were adjusted for age and 
use of variety of drugs. T test (for normal distribution) or 
Mann–Whitney test (for non-normal distribution) was 
used to compare each parameter between two groups. 
An ANOVA test was used to identify parameters that 
would make significant differences between more than 
two groups; Scheffe’s test was then used to test the signif-
icance of difference in each identified parameter between 
any two groups. Genotype and allele evaluation, regard-
ing their relationship with a given feature, e.g., a risk for 
disease, was supported by an analysis of OR and 95 % CI, 
calculated according to the logistic regression model. The 
wild type of genotype and allele was a reference group. 
The Statistica v. 7.0 software package (StatSoft, Tulsa, 
OK, USA) was used.
Results
It was demonstrated that the MDR1 gene C3435T poly-
morphism may be associated with the incidence of DRE 
in Polish children.
See Table  3 for the distribution of genotypes and the 
incidence of alleles in the group of DRE and in the group 
of non-epileptic children. Statistically significant dif-
ferences were demonstrated in genotype distribution 
between the study groups (p  <  0.05). The CC genotype 
occurred in the patients with statistically significantly 
higher frequency, while the TT homozygote was found 
with statistically significantly lower frequency vs. the 
group of healthy controls (p < 0.05). It was demonstrated 
that the C allele in those children may be a risk factor for 
DRE, unlike the T allele which, by contrast, may play a 
protective role (OR 0.53; 95 % CI, 0.33–0.85; p = 0.012).
The observed genotype frequency of MDR1 C3435T 
in the controls group were in agreement with HWE 
(p > 0.05). In case of the C3435T polymorphism of MDR1 
gene the distribution of the genotypes in the patients 
differed significantly from one expected from HWE 
(p < 0.05). It is caused by the very low abundance of the 
MDR1 TT genotype in the examined Polish population.
Similar results were observed when the group of epi-
leptic non-responders was compared with the respond-
ers (see Table 4). The CC homozygote in the patients with 
DRE occurred with a statistically significantly higher fre-
quency (33 %), while the TT homozygote demonstrated 
a statistically significantly lower frequency (30  %) vs. 
the group of children with therapy-responding epilepsy 
(CC-24  %, TT-49  %). The C allele in the patients with 
DRE occurred with a statistically significantly higher fre-
quency (51 %), while the T allele demonstrated a statisti-
cally significantly lower frequency (49 %) vs. the group of 
children therapy-responding epilepsy (C-37  %, T-63  %). 
The C allele in those children may be a risk factor for 
DRE. The T allele may then play a protective role (OR 
0.56 95 % CI 0.36–0.87; p = 0.014).
No statistically significant differences were demon-
strated in the distribution of genotypes between the 
group of responders and healthy controls (p > 0.05) (see 
Table 5).
No differences were found in the study groups, either 
in genotype or allele distribution in reference to patient’s 
gender or concomitant diseases (p > 0.05).
Table 2 Primer sequences and  conditions for  real-time PCR and  the following  HRM analysis of  the examined MDR1 
C3435T




30 s for 95 °C 30 s for 58 °C 30 s for 72 °C 75–90 °C
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Discussion
The MDR1 gene polymorphism, while structuring the 
variable expression of P-gp, may then control the efficacy 
of anti-epileptic therapy. An increased expression of this 
gene leads to higher volumes of P-gp in the endothelial 
cells of the blood–brain barrier and in astrocytes. This 
Table 3 Distributions of TT, CT and CC genotypes and T and C alleles in C3435T polymorphism of MDR1 gene in the group 
of children with drug-resistant epilepsy and in the group of healthy children
a Crude odds ratio (OR), 95 % CI confidence interval at 95 %
b Adjusted for age and use of variety of drugs
c for the test of χ2 conformity with the distribution predicted by the Hardy–Weinberg law
d Reference group—wild type of allele
Children with drug-resistant  
epilepsy (n = 106)
Healthy children (n = 98) OR (95 % CIa)b pc
Number (%) Number (%)
CC 35 33 16 16 1.00 Ref.d
CT 39 37 37 38 0.48 (0.23–1.01) 0.079
TT 32 30 45 46 0.33 (0.15–0.68) 0.005
C 109 51 69 35 1.00 Ref.
T 103 49 127 65 0.53 (0.33–0.85) 0.012
Table 4 Distributions of TT, CT and CC genotypes and T and C alleles in C3435T polymorphism of MDR1 gene in the group 
of children with drug-resistant epilepsy and in the group of drug-responsive epilepsy
a Analysis of odds ratio (OR odds ratio, PU Confidence Interval 95 %)
b Adjusted for age and use of variety of drugs
c For the test of χ2 conformity with the distribution predicted by the Hardy–Weinberg law
d Reference group—wild type of allele
Children with drug-resistant  
epilepsy (n = 106)
Children with drug-responsive  
epilepsy (n = 67)
OR (95 % CIa)b pc
Number (%) Number (%)
CC 35 33 16 24 1.00 Ref.d
CT 39 37 18 27 0.99 (0.44–2.23) 0.862
TT 32 30 33 49 0.44 (0.21–0.95) 0.036
C 109 51 50 37 1.00 Ref.
T 103 49 84 63 0.56 (0.36–0.87) 0.014
Table 5 Distributions of TT, CT and CC genotypes and T and C alleles in C3435T polymorphism of MDR1 gene in the group 
of children with drug-responsive epilepsy and in the group of healthy children
a Analysis of odds ratio (OR odds ratio, PU Confidence Interval 95 %)
b Adjusted for age and use of variety of drugs
c For the test of χ2 conformity with the distribution predicted by the Hardy–Weinberg law
d Reference group—wild type of allele
Children with drug-responsive  
epilepsy (n = 67)
Healthy children (n = 98) OR (95 % CIa)b pc
Number (%) Number (%)
CC 16 24 16 16 1.00 Ref.d
CT 18 27 37 38 0.48 (0.19–1.18) 0.172
TT 33 49 45 46 0.73 (0.32–1.67) 0.596
C 50 37 69 35 1.00 Ref.
T 84 63 127 65 0.92 (0.58–1.44) 0.777
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process results in decreased parenchymal concentra-
tions of drugs, despite their achieved therapeutic lev-
els in blood [18, 19]. It should be emphasised that the 
majority of data from world literature concerns SNPs of 
MDR1-C3435T.
In the presented study, a genetic evaluation was per-
formed of the MDR1 gene C3435T polymorphism in 
order to define its association with DRE in the popula-
tion of Polish children. This polymorphism was selected 
on the basis of the earlier mentioned literature data, 
which are suggestive of its correlations with DRE [8–11]. 
Studies of this type have been rather scarce in the world 
perspective, what raised our interest in this challenging 
issue.
The polymorphisms of MDR1 gene, including C3435T 
polymorphism, were analysed by Alpman et  al. [17] 
in a group of 39 children with DRE vs. a control group 
(n  =  92). A conclusion was drawn that the polymor-
phisms of MDR1 gene were not associated with mul-
tidrug resistance but that CC3435/GG2677 genotypes 
might affect the efficacy of administered therapies in 
cases of DRE.
Shaheen et  al. [15] studied the functional importance 
of C3435T polymorphism in a population of epileptic 
children in the southern India. The risk of non-respon-
siveness to therapy was much higher in patients, being 
the carriers of TT genotype vs. CC homozygotic patients. 
The researchers suggested that C3435T polymorphism 
could be related to DRE, however, further studies in dif-
ferent ethnic populations are necessary to explain the 
role of the polymorphism in DRE patients.
However, there are also reports which do not con-
firm the relationship between C3435T polymorphism of 
MDR1 gene and DRE in children [12, 14, 16].
In Poland, two reports have been published on this 
issue, describing a study of C3435T polymorphism in a 
group of children from the Silesian region [20, 21]. The 
obtained results suggest no relationship between the 
occurrence of DRE and the above-mentioned polymor-
phism of MDR1 gene in the population of Polish chil-
dren. Following the authors’ suggestions, further genetic 
studies are necessary to better understand the causes 
of DRE, which may help in developing a more effective 
therapy.
In contrast to those reports, in this reported study, the 
influence of C allele on the risk of DRE in children was 
found and confirmed. An increased incidence rate of CC 
genotype was found in the group of non-responders to 
therapy vs. both the responders and healthy controls. A 
decreased incidence rate of TT homozygote was found 
in the group of non-responders to therapy vs. both the 
responders and healthy controls. It suggests that the T 
allele may play a protective role.
It is possible that the presence of MDR1 allele remains 
in a linkage disequilibrium with another, so far unknown, 
mutation, which may be important, regarding P-gp con-
centrations in plasma.
A number of hypotheses try to explain the relation-
ship between the MDR1 C3435T polymorphism and the 
activity of P-gp. The first hypothesis assumes some con-
jugation of 3435T allele, which correlates with decreased 
transporter activity, with G2677 (A, T) changes, lead-
ing to modifications in the sequence of amino acids 
(Val > Ser, Val > Thr). A consequence of these changes is 
different stability and activity of this protein [22, 23].
Since this conjugation is not complete and its degree 
differs in particular populations, the above-mentioned 
correlation was not observed in all the reported studies. 
The presence of other, missense type, polymorphisms, 
e.g., C1236T, may be an additional worrying factor [22]. 
Another theory assumes a correlation of the C3435T 
polymorphism with other, still not identified changes in 
the regulatory domains of this gene, which may affect its 
expression levels. However, there is no reliable literature 
data to support this hypothesis.
The obtained results demonstrate a possibility of a 
relationship between C3435T polymorphism and the 
incidence rate of DRE in the population of the Polish chil-
dren. However, it requires further studies on much larger 
study groups. Still, one cannot exclude a possible influ-
ence of the studied polymorphism on epilepsy develop-
ment in result of combined effects with other factors. For 
the process of epilepsy development is complicated and 
demanding a complex participation of multiple factors.
Drawing conclusions from obtained data should be 
done with a substantial level of caution due to the limi-
tations affecting this study: test group and controls may 
be quantitatively unsatisfactory, SNPs linkage disequi-
librium was not considered, circulating P-gp levels in 
patients were unknown and the relation between SNP 
C3435T in MDR1 and P-gp expression has not been 
stated. Among the abundance of genetic polymorphisms 
in MDR1 gene only one polymorphism of MDR1 was 
analysed without respect to linkage disequilibrium, 
which is a crucial feature of population genetics. A joint 
analysis of SNP C3435T of MDR1 and other SNPs in 
MDR1 could shed a new light on the role of SNPs in DRE.
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